An in-depth look at how tyrosine kinase inhibitors (TKIs), a type of targeted therapy, are used to treat chronic myeloid leukemia (CML).
This guide includes explanations from top hematologists about how tyrosine kinase inhibitors (TKIs) are used to treat chronic myeloid leukemia (CML).
TKIs are targeted therapy drugs that block the effects of BCR:ABL1 (the abnormal protein found in people with CML). In this guide, the featured doctors explain how they are taken, why they have been so successful in treating people with CML, and what side effects may occur.
Dr. Rodrigo Leão Edelmuth
Tyrosine kinase inhibitors (TKIs) are a type of targeted therapy that go after the abnormal BCR-ABL1 protein that causes uncontrolled CML cell growth and block its function, causing the CML cells to die.
